NASDAQ · INDP
Indaptus Therapeutics, Inc.
$3.34+$0.01 (+0.3%)
Indaptus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.96% below the high.
Loading market information…
NASDAQ · ENVB · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Enveric Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.98% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Enveric Biosciences, Inc.’s next earnings report is currently expected on Nov 12, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Enveric Biosciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q3 2024 | Nov 14, 2024 | -$43.20-8,207.69% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.34+$0.01 (+0.3%)
Indaptus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.96% below the high.
$0.53-$0.01 (-1.26%)
Jasper Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.55% below the high.
$0.84+$0.19 (+29.23%)
Salarius Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.41% below the high.
$0.76-$0.15 (-16.31%)
Azitra, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.08% below the high.
$0.59-$0.01 (-1.99%)
Onconetix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.71% below the high.
$0.14-$0.01 (-6.67%)
Hepion Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 36.36% below the high.
$0.71-$0.12 (-14.18%)
SciSparc Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.69% below the high.
$0.52-$0.02 (-2.92%)
Scinai Immunotherapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 96.65% below the high.
